To provide an excellent therapeutic or prophylactic agent for cardiovascular diseases on the basis of cGMP production-increasing activity attributed to soluble guanylate cyclase-activating activity. It was discovered that an imidazopyridine compound having a carbamoyl group at the 3-position of an imidazo[1,2-a]pyridine skeleton and having a substituent attached to the 8-position of the skeleton through an oxygen atom exhibits cGMP production-increasing activity attributed to potent soluble guanylate cyclase-activating activity and can be used in an excellent therapeutic or prophylactic agent for various cardiovascular diseases associated with soluble guanylate cyclase, and the invention was completed.本發明係關於提供一種依據藉由可溶性胍裂解環化酶活化作用之cGMP產生增強作用之優良心血管疾病的治療或預防藥。本發明為發現具有咪唑並[1,2-a]吡啶骨架的第3位上介著胺基甲醯基及第8位介著氧原子而結合之取代基之咪唑並吡啶化合物，其顯示強力藉由可溶性胍裂解環化酶活化作用之cGMP產生增強作用，可成為與可溶性胍裂解環化酶相關的種種心血管疾病之優良治療或預防藥，而完成本發明。
